Results 151 to 160 of about 79,534,328 (299)

TRAIP Mediates Alcohol‐Induced Liver Injury through Regulating β‐catenin Ubiquitin Degradation via Direct Interaction

Advanced Science, EarlyView.
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu, Mingjiang Liu, Lijuan Liao, Zhaohong Mo, Wenli Xu, Linfeng Mao, Yubing Chen, Qiuli Xie, Ming Yao, Shilian Chen, Stephen Tomlinson, Sebastian Mueller, Songqing He, Guandou Yuan   +13 more
wiley   +1 more source

Building an Interleukin-10-Producing Identity: How B Cells Acquire Interleukin-10 Competence and How Plasma Cell Differentiation Consolidates This Program. [PDF]

Immunol Rev
Cuc BT, Tong Y, Wu Z, Alvarez-Simon D, Fillatreau S.   +4 more
europepmc   +1 more source

Disrupted TFEB/GDNF–cAMP/ATP Coupling Underlies Astrocytic Dysfunction and Depression in LRRK2 G2019S Parkinson's Mice

Advanced Science, EarlyView.
ABSTRACT The LRRK2 G2019S mutation, a Parkinson's disease–linked variant, has been associated with depression‐like phenotypes, but mechanisms remain unclear. We chart age‐dependent behavioral changes and astrocyte reactivity in G2019S mice and define a pathway connecting LRRK2 to TFEB/GDNF signaling, cellular energetics, and inflammation.
Longping Yao, Maryam Hatami, Sumeyye Koc, Qing Jiang, Thomas Skutella, Yuanfeng Zhang   +5 more
wiley   +1 more source

Interleukin-6 and tumor necrosis factor-α are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness

, 2004
Interleukin-6 and tumor necrosis factor-α are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin ...
MA Febbraio (9644273), Clinton Bruce (13064589), AL Carey (14534870), M Sacchetti (13701022), MJ Anderson (8365899), B Saltin (13701028), JA Hawley (9629840), DB Olsen (15871553)   +7 more
core  

Interleukin-10 enhances IgG galactosylation and sialylation. [PDF]

Biomark Res
Lunding HB, Wasynczuk AM, Bartsch YC, Buhre JS, Nouta J, Leliavski A, Lehrian S, Becker AE, Manzhula K, Köcher P, Mehlfeld J, Rahmöller J, Wuhrer M, Ehlers M.   +13 more
europepmc   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Interleukin-10 at the crossroads of immunity in TLR7-induced lupus. [PDF]

Front Immunol
Williams JP, Amend A, Schäfer AL, Ruiz-Aparicio PF, Kraemer AN, Luo AQ, Riechert L, Weber L, Keller B, Manz RA, Voll RE, Chevalier N.   +11 more
europepmc   +1 more source

An Activity‐Reinforced P‐Modified Single‐Atom Cu Nanozyme Potentiates IDO Blockade‐Induced Tumor Radiotherapy

Advanced Science, EarlyView.
A phosphorus‐modified single‐atom copper nanozyme delivering the IDO1 inhibitor 1‐methyl‐tryptophan enhances breast cancer radioimmunotherapy by simultaneously relieving hypoxia and inducing immunogenic cell death through dual enzyme activities while blocking tryptophan metabolism to suppress regulatory T cell function.
Wei Zhao, Songliu Hu, Zhanggui Wang, Liqun Wang, Liming Zhang, Qi Li, Hua Tang, Yang Zhong, Zhongxian Zhang, Kelong Fan, Shipeng Ning, Xiyun Yan   +11 more
wiley   +1 more source

Plasma Interleukin-10 Levels and IL10 Genetic Variants Are Associated With Clinical Outcomes in Patients With Severe COVID-19 Treated With Corticosteroids. [PDF]

J Med Virol
Fricke-Galindo I, Ortega-Villafuerte FM, Pérez-Rubio G, Buendía-Roldán I, Ramírez-Bello J, Castillo Morales AA, Chávez-Galán L, de Jesús Hernández-Zenteno R, Ramos-Martínez E, García-Carmona S, Cataneo-Piña DJ, Bautista-Félix NE, Falfán-Valencia R.   +12 more
europepmc   +1 more source

In Situ Genetic Engineering Facilitates MMP‐9‐Responsive TIMP1 Release Through Proteolytic Cleavage to Boost Diabetic Wound Healing

Advanced Science, EarlyView.
This study develops an MMP‐9‐responsive protein release system that transforms resident cells into drug depots through in situ genetic engineering. Anchored to the membrane, the therapeutic protein TIMP1 is selectively released upon MMP‐9 cleavage.
Yuan Zhang, Jiani Deng, Man Yee Cheung, Tingting Fu, Xufeng Qi, Dongqing Cai, Jianmin Sun, Gang Lu, Peng Shi, Wai‐Yee Chan, Xu Li, Hui Zhao   +11 more
wiley   +1 more source